Universität zu Köln

Kruger, Stephan F., Cadilha, Bruno L., von Bergwelt-Baildon, Michael, Endres, Stefan and Kobold, Sebastian (2020). Challenges in Clinical Trial Design for T Cell-Based Cancer Immunotherapy. Clin. Pharmacol. Ther., 107 (1). S. 47 - 50. HOBOKEN: WILEY. ISSN 1532-6535

Full text not available from this repository.

Abstract

Chimeric antigen receptor T cells can induce impressive response rates in patients with refractory B cell malignancies. Adoptive transfer of tumor infiltrating lymphocytes or T cell receptor-engineered T cells are other promising treatment modalities currently in clinical development. Requirements for clinical trial design for T cell-based cancer immunotherapy significantly differ from established criteria for small-molecule or antibody-based anticancer drugs. Here, we highlight important differences regarding preclinical development, trial design, and reporting of clinical trials.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Kruger, Stephan F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Cadilha, Bruno L. UNSPECIFIED UNSPECIFIED UNSPECIFIED von Bergwelt-Baildon, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Endres, Stefan UNSPECIFIED UNSPECIFIED UNSPECIFIED Kobold, Sebastian UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-352818
DOI:	10.1002/cpt.1659
Journal or Publication Title:	Clin. Pharmacol. Ther.
Volume:	107
Number:	1
Page Range:	S. 47 - 50
Date:	2020
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1532-6535
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language Pharmacology & Pharmacy Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/35281